Platform

Dermatology: A Complex but Crucial Therapeutic Area

Dermatological diseases encompass a wide spectrum, from common conditions such as atopic dermatitis, psoriasis, and acne to more severe or rare disorders like systemic sclerosis, skin fibrosis, and photodamage. These diseases not only cause chronic inflammation, itching, and pain but also lead to psychological burden and social stigmatization. Developing safe and effective dermatological therapies relies heavily on robust preclinical models that accurately reflect human pathology and treatment responses.

KCI Biotech, as a CRO specializing in dermatology, provides comprehensive in vivo pharmacology and efficacy testing to support preclinical drug discovery and evaluation in dermatological indications.

Our Dermatology Disease Models

KCI Biotech offers a broad portfolio of dermal preclinical models to meet diverse research needs.

We provide animal models across mouse, rat, rabbit, pig, and dog, covering both acute and chronic skin diseases:

Atopic Dermatitis Models

• Calcipotriol (MC903)-induced model
• Oxazolone-induced model
• Ovalbumin (OVA)-induced model
• OVA combined with the MC903-induced model

Psoriasis Models

• Imiquimod-induced psoriasis-like model

Systemic Sclerosis (Scleroderma) Models

• Bleomycin-induced skin fibrosis model

Skin Scar Model

• Mouse tail scarring model

Skin Defect Healing Models

• Skin Scalding Model
• Skin defect healing model
• Streptozotocin (STZ)-induced skin defect/scald model in type I diabetes mellitus
• Streptozotocin (STZ)-induced type I diabetic foot ulcer model 

Photodamage Models

Pressure Ulcer Models

• Chronic pressure injury simulation model

Each model is validated with reproducible biomarkers, histopathological characteristics, and quantifiable efficacy endpoints, enabling translational relevance for human clinical applications.

Why Choose KCI Biotech as Your Dermatology CRO Partner

Specialized Expertise in Dermatology Pharmacology

KCI Biotech is a CRO with deep expertise in dermatology preclinical studies, integrating pharmacology, toxicology, and pathology to support the development of topical, transdermal, and systemic skin therapies. Our team has extensive experience in evaluating anti-inflammatory, immunomodulatory, anti-fibrotic, and wound-healing mechanisms in various dermal models.

Advanced Laboratory Animal Platforms

We operate two AAALAC-accredited animal facilities with a total area of over 40,000 m², equipped for multiple species and disease models. The facilities meet international GLP standards and are designed to support all types of in vivo dermatology research, ensuring data reliability and regulatory compliance.

Proven Track Record with Global Partners

With 1,000+ domestic and international pharmaceutical collaborations and 100+ IND submissions, KCI Biotech is recognized as a trusted preclinical CRO in dermatology research. Our established experience helps streamline study design, regulatory preparation, and translational data interpretation.

Customized Study Design & Rapid Turnaround

We tailor every study based on compound characteristics, target mechanism, and clinical translation goals. KCI Biotech offers professional CRO services to ensure that each dermatology preclinical study is both scientifically rigorous and cost-efficient.

Partner with KCI Biotech for Dermatology Drug Discovery

From model selection to data interpretation, KCI Biotech’s dermatology CRO services help bridge the gap between basic research and clinical success.

Whether your focus is on atopic dermatitis, psoriasis, fibrosis, or wound repair, our dermal preclinical models and in vivo pharmacology expertise can accelerate the path toward safer and more effective dermatological therapies.

Contact KCI Biotech to discuss customized dermatology CRO solutions for your preclinical drug development.